Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial

ASTONISH investigators; Bruno François; Simon Lambden; Tom Fivez; Ville Pettilä; Thorbjørn Grøfte

doi:10.1016/S2213-2600(23)00158-3

Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial

ASTONISH investigators, Bruno François, Simon Lambden, Tom Fivez, Ville Pettilä, Thorbjørn Grøfte

Research output: Contribution to journal › Article › Scientific › peer-review

Original language	English
Journal	The Lancet respiratory medicine
Volume	11
Issue number	10
Pages (from-to)	894-904
Number of pages	11
ISSN	2213-2600
DOIs	https://doi.org/10.1016/S2213-2600(23)00158-3
Publication status	Published - Oct 2023
MoE publication type	A1 Journal article-refereed

Bibliographical note

Publisher Copyright:
© 2023 Elsevier Ltd

Fields of Science

3126 Surgery, anesthesiology, intensive care, radiology
3121 General medicine, internal medicine and other clinical medicine

Access to Document

10.1016/S2213-2600(23)00158-3

Cite this

ASTONISH investigators, François, B., Lambden, S., Fivez, T., Pettilä, V., & Grøfte, T. (2023). Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial. The Lancet respiratory medicine, 11(10), 894-904. https://doi.org/10.1016/S2213-2600(23)00158-3

@article{cec942ac4d684c7db577c0309c4438b1,

title = "Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial",

keywords = "3126 Surgery, anesthesiology, intensive care, radiology, 3121 General medicine, internal medicine and other clinical medicine",

author = "{ASTONISH investigators} and Bruno Fran{\c c}ois and Simon Lambden and Tom Fivez and Sebastien Gibot and Marc Derive and Grouin, {Jean Marie} and Margarita Salcedo-Magguilli and J{\'e}r{\'e}mie Lemari{\'e} and {De Schryver}, Nicolas and Ville Jalkanen and Tarik Hicheur and Garaud, {Jean Jacques} and Val{\'e}rie Cuvier and Ricard Ferrer and Morten Bestle and Ville Pettil{\"a} and Mira, {Jean Paul} and Camille Bouisse and Emmanuelle Mercier and Joris Vermassen and Vincent Huberlant and Isabelle Vinatier and Nadia Anguel and Mitchell Levy and Laterre, {Pierre Fran{\c c}ois} and Pierre Asfar and Nay, {Mai Anh} and Christophe Guitton and Quenot, {Jean Pierre} and David Tran-Van and Julien Bohe and Ga{\"e}tan Plantef{\`e}ve and Saadalla Nseir and Lefrant, {Jean Yves} and Xavier Monnet and Laurent Papazian and Christophe Vinsonneau and Constantin, {Jean Michel} and Alexandre Mebazaa and Haikel Oueslati and Dolores Escudero and {Martinez Sagasti}, Fernando and Enrique Piacentini and {Ramirez Galleymore}, Paula and Thierry Dugernier and David Fagnoul and Isabelle Michaux and Allan Seibert and Matti Reinikainen and Thorbj{\o}rn Gr{\o}fte",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Ltd",

year = "2023",

month = oct,

doi = "10.1016/S2213-2600(23)00158-3",

language = "English",

volume = "11",

pages = "894--904",

journal = "The Lancet respiratory medicine",

issn = "2213-2600",

publisher = "Elsevier Ltd. ",

number = "10",

}

ASTONISH investigators, François, B, Lambden, S, Fivez, T, Pettilä, V & Grøfte, T 2023, 'Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial', The Lancet respiratory medicine, vol. 11, no. 10, pp. 894-904. https://doi.org/10.1016/S2213-2600(23)00158-3

Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial. / ASTONISH investigators; François, Bruno; Lambden, Simon et al.
In: The Lancet respiratory medicine, Vol. 11, No. 10, 10.2023, p. 894-904.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH)

T2 - a double-blind, randomised, controlled, phase 2b trial

AU - ASTONISH investigators

AU - François, Bruno

AU - Lambden, Simon

AU - Fivez, Tom

AU - Gibot, Sebastien

AU - Derive, Marc

AU - Grouin, Jean Marie

AU - Salcedo-Magguilli, Margarita

AU - Lemarié, Jérémie

AU - De Schryver, Nicolas

AU - Jalkanen, Ville

AU - Hicheur, Tarik

AU - Garaud, Jean Jacques

AU - Cuvier, Valérie

AU - Ferrer, Ricard

AU - Bestle, Morten

AU - Pettilä, Ville

AU - Mira, Jean Paul

AU - Bouisse, Camille

AU - Mercier, Emmanuelle

AU - Vermassen, Joris

AU - Huberlant, Vincent

AU - Vinatier, Isabelle

AU - Anguel, Nadia

AU - Levy, Mitchell

AU - Laterre, Pierre François

AU - Asfar, Pierre

AU - Nay, Mai Anh

AU - Guitton, Christophe

AU - Quenot, Jean Pierre

AU - Tran-Van, David

AU - Bohe, Julien

AU - Plantefève, Gaëtan

AU - Nseir, Saadalla

AU - Lefrant, Jean Yves

AU - Monnet, Xavier

AU - Papazian, Laurent

AU - Vinsonneau, Christophe

AU - Constantin, Jean Michel

AU - Mebazaa, Alexandre

AU - Oueslati, Haikel

AU - Escudero, Dolores

AU - Martinez Sagasti, Fernando

AU - Piacentini, Enrique

AU - Ramirez Galleymore, Paula

AU - Dugernier, Thierry

AU - Fagnoul, David

AU - Michaux, Isabelle

AU - Seibert, Allan

AU - Reinikainen, Matti

AU - Grøfte, Thorbjørn

PY - 2023/10

Y1 - 2023/10

KW - 3126 Surgery, anesthesiology, intensive care, radiology

KW - 3121 General medicine, internal medicine and other clinical medicine

U2 - 10.1016/S2213-2600(23)00158-3

DO - 10.1016/S2213-2600(23)00158-3

M3 - Article

C2 - 37269870

AN - SCOPUS:85164824971

SN - 2213-2600

VL - 11

SP - 894

EP - 904

JO - The Lancet respiratory medicine

JF - The Lancet respiratory medicine

IS - 10

ER -

ASTONISH investigators, François B, Lambden S, Fivez T, Pettilä V, Grøfte T. Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial. The Lancet respiratory medicine. 2023 Oct;11(10):894-904. doi: 10.1016/S2213-2600(23)00158-3